Cargando…

Dyslipidemia is a Risk Factor for the Incidence and Severity of Drug-Induced Liver Injury (DILI): A Retrospective Population-Based Study in China

BACKGROUND: A Chinese population-based study aimed to investigate the risk factors for the incidence and severity of drug-induced liver injury (DILI) from Chinese herbal medicines and conventional Western medicines. MATERIAL/METHODS: Liver biopsy and routine laboratory testing, including serum lipid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xu, Wang, Le, Li, Dezhao, Niu, Junqi, Gao, Pujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515978/ https://www.ncbi.nlm.nih.gov/pubmed/31059494 http://dx.doi.org/10.12659/MSM.916687

Ejemplares similares

Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury
por: Li, Xu, et al.
Publicado: (2019)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012)

Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
por: Quintás, Guillermo, et al.
Publicado: (2021)

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
por: Moreno-Torres, Marta, et al.
Publicado: (2022)

Landscape of DILI-related adverse drug reaction in China Mainland
por: Wang, Jiabo, et al.
Publicado: (2022)

Accuracy of gamma-glutamyl transpeptidase-to-platelet ratio (GPR), red cell distribution width (RDW), aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis-4 index (FIB4) compared with liver biopsy in patients with drug-induced liver injury (DILI)
por: Wan, Minjie, et al.
Publicado: (2021)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021)

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues
por: Teschke, Rolf, et al.
Publicado: (2021)

Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
por: Danjuma, Mohammed, et al.
Publicado: (2020)

Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
por: Tátrai, Péter, et al.
Publicado: (2022)

The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI)
por: Ghallab, Ahmed
Publicado: (2014)

Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure
por: Liu, Anika, et al.
Publicado: (2021)

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
por: Brennan, Paul N, et al.
Publicado: (2021)

DILI( C ): An AI-Based Classifier to Search for Drug-Induced Liver Injury Literature
por: Rathee, Sanjay, et al.
Publicado: (2022)

The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
por: Walker, Paul A., et al.
Publicado: (2020)

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
por: Segovia-Zafra, Antonio, et al.
Publicado: (2021)

Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
por: Zachou, Maria, et al.
Publicado: (2022)

Increased red cell distribution width predicts severity of drug-induced liver injury: a retrospective study
por: Li, Xu, et al.
Publicado: (2021)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints
por: Liu, Xiaobin, et al.
Publicado: (2020)

Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
por: Villanueva-Paz, Marina, et al.
Publicado: (2021)

Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
por: Bessone, Fernando, et al.
Publicado: (2022)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

2409. Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients Treated With Aztreonam and Ceftazidime
por: Saade, Elie, et al.
Publicado: (2018)

A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT)
por: Tillmann, Hans L., et al.
Publicado: (2022)

Characteristics of Drug-induced Liver Injury in Chronic Liver Disease: Results from the Thai Association for the Study of the Liver (THASL) DILI Registry
por: Chirapongsathorn, Sakkarin, et al.
Publicado: (2023)

The Promise of AI for DILI Prediction
por: Vall, Andreu, et al.
Publicado: (2021)

Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score
por: Danjuma, Mohammed Ibn-Mas’ud, et al.
Publicado: (2020)

Novel biomarkers for potential risk stratification of drug induced liver injury (DILI): A narrative perspective on current trends
por: Danjuma, Mohammed Ibn-Mas’ud, et al.
Publicado: (2019)

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
por: Regev, Arie, et al.
Publicado: (2014)

Deriving time-concordant event cascades from gene expression data: A case study for Drug-Induced Liver Injury (DILI)
por: Liu, Anika, et al.
Publicado: (2022)

Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM)
por: Teschke, Rolf, et al.
Publicado: (2021)

A novel phenotype‐based drug‐induced liver injury causality assessment tool (DILI‐CAT) allows for signal confirmation in early drug development
por: Hermann, Richard P., et al.
Publicado: (2022)

Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study
por: M'Kada, Helmi, et al.
Publicado: (2012)

Biomarkers in DILI: One More Step Forward
por: Robles-Díaz, Mercedes, et al.
Publicado: (2016)

Mechanistic Studies of Idiosyncratic DILI: Clinical Implications
por: Uetrecht, Jack
Publicado: (2019)

Relationships between Metabolic Comorbidities and Occurrence, Severity, and Outcomes in Patients with Acute Pancreatitis: A Narrative Review
por: Li, Xu, et al.
Publicado: (2019)

Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center
por: Li, Xu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fe77hvsepf2dt0tdsnq275a5vq